Correlation between Lactate Dehydrogenase Levels and Severity by Pulmonary Tomography in Patients with Sars-Cov-2
Main Article Content
Abstract
Serum lactate dehydrogenase (LHD) concentration has been described as a biomarker to predict severe lung injury and severe hypoxemia in patients with ARDS. The aim of the study was to correlate lactate dehydrogenase concentrations with the tomographic severity index in SARS-CoV-2 pneumonia cases, considering lung CT as the gold standard for severity diagnosis in this population based on the presence of ground glass pattern and the score given in the segmental assessment. A total of 110 patients were included in the study, in the period from April to September 2020. From the results, a moderate correlation was obtained between serum LHD levels and severity score by pulmonary tomography, with an r=0.474 and p <0.0001; with a severity-associated serum LHD cut-off point of 396 mg /dl (p < 0.001, sensitivity 86.02%, specificity 75%, AUC 0.806). Serum DHL levels may be useful for predicting severity in patients with COVID pneumonia 19t.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. COVID-19: chronology of WHO action [online] WHO; 27 April 2020 www.who.int.
II. COVID-19 in Mexico: cases by entity and chronology of the coronavirus [online] Mexico City. La Razón; 2020.
III. Gandhi R, Lynch J, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 29;383(18):1757–66.
IV. Lauer S, Grantz K, Bi Q, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 5;172(9):577–82.
V. Verity R, Okell L, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20: 669–77
VI. Merino M, Sahuaquillo J, Borrull A, et al. ¿Es el lactato un buen indicador de hipoxia tisular? Resultados de un estudio piloto en 21 pacientes con un traumatismo craneoencefálico. Neurocirugía 2010; 21: 289-301.
VII. Adeva M, López M, Funcasta R, et al. Comprehensive review on lactate metabolism in human health. Mitochondrion 17 (2014) 76–100.
VIII. Sánchez M, Olive C, Caballero M, et al. Isoenzimas de lactato deshidrogenasa en el suero y aspirado bronquial de recién nacidos con dificultad respiratoria de etiología diversa. An Esp Pediatr 1996;45:62-66.
IX. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Critical Care (2020) 24:154.
X. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 20;382(8):727–33.
XI. Giwa A, Desai A. Novel Coronavirus COVID-19: an Overview for emergency clinicians. Emerg Med Pract 2020 Feb 27;22(2 Suppl 2):1-21
XII. Sánchez M, Carrillo R. Coronavirus-2019. Consideraciones Generales. Rev Mex Anestesiol, 2020; 43 (2): 83-91.
XIII. Baig A, Khaleeq A, Ali U, et al. Evidence of the COVID-19 Virus Targeting the CNS: tissue distribution, host-virus interaction and proposed neurotropic mechanisms. ACS Chem. Neurosci. XXXX, XXX, XXX−XXX.
XIV. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020; 46(6): 1099–1102.
XV. Mendoza A, Valencia G, Quintana A, et al. Clasificación clínica y tratamiento temprano de la COVID-19: reporte de casos del Hospital de Emergencias Villa El Salvador, Lima Perú. Acta Med Peru. 2020;37(2)
XVI. Elizalde J, Fortuna J, Luviano J, et al. Guía COVID-19 para la atención del paciente crítico con infección por SARS-coV-2 Colegio Mexicano de Medicina Crítica. Med Crit 2020;34(1):7-42
XVII. Truog R, Mitchell C, Daley G. The toughest triage - allocating ventilators in a pandemic. N Engl J Med 2020; 382:1973-1975.
XVIII. Prokop M, Van Everdingen W, Van Rees V, et al. CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID 19 definition and evaluation. Radiology 2020; 296:E97–E104.
XIX. Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 2020; 296:E55–E64.
XX. Kelly R, Greiff D. The level of lactic dehydrogenase activity as an indicator of the grwoth of influenza virus in the embryonate egg. J Exp Med. 1961 Jan 1;113(1):125-9.
XXI. García A, Rosas M, SantoyoA, et al. Deshidrogenasa láctica como factor pronóstico en neumonías. Med Int Méx. 2017 September;33(5):563-571.
XXII. Aranda E. Interpretación de la deshidrogenasa láctica. Rev Soc Bol Ped 2010; 49 (2): 132 - 4
XXIII. Goulabchand R, Guilpain P. Anomalías biológicas frecuentes: lactato deshidrogenasa elevada. EMC - Tratado de Medicina, 20(4), 1–5.
XXIV. Fernández J, Hinestroza L, Villasmil E, et al. Deshidrogenasa láctica sérica en pacientes con neumonía adquirida en la comunidad. Pulmón. 6. 19.
XXV. Fink M. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin. 2001 Jan;17(1):219-37.
XXVI. Garrido C, Cano C, Salcedo M, et al. Influenza A H1N1 (swine flu) en niños estudiados en el Instituto Nacional de Enfermedades Respiratorias. Acta Pediatr Mex 2010;31(4):162-167.
XXVII. Caprotta G, González P, Primucci Y, et al. Infección respiratoria por influenza A H1N1 en cuidados intensivos de la República Argentina. An Pediatr(Barc).2010;72(1):62–66.
XXVIII. Lu J, Wei Z, Jiang H, et al. Lactate dehydrogenase is associated with 28 day mortality in patients with sepsis: a retrospective observational study. J Surg Res. 2018 Aug;228:314-321.
XXIX. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: The CALL score. Clin Infect Dis. 2020 Sep 12;71(6):1393-1399.
XXX. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System inhibitors in patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659.
XXXI. Fernández J, Hinestroza L, Villasmil E, [et al]. Deshidrogenasa láctica sérica en pacientes con neumonía adquirida en la comunidad” Pulmón 6. Enero 2015
XXXII. Neri S, Barranco G, León M, et al. Factores predictores de defunción en pacientes con neumonía por influenza A H1N1. Med Int Mex. 2011;27(5):421-428.
XXXIII. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY). 2020;12(12):11245-11258.
XXXIV. Ma C, Gu J, Hou P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta analysis. medRxiv 2020.03.17.20037572.
XXXV. Ferrando C, Mellado R, Gea A, et al. Características, evolución clínica y factores asociados a la mortalidad en UCI de los pacientes críticos infectados por SARS-CoV-2 en España: estudio prospectivo, de cohorte y multicéntrico. Rev Esp Anestesiol Reanim. 2020;67(8):425---437.
XXXVI. Tan L, Kang X, Ji X, et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. Med (N Y). 2020;1(1):128-138.e3.
XXXVII. Iba T, Levy J, Levi M, et al. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020;48(9):1358-1364.
XXXVIII. Peng Q, Wang X, Zhang L, et al. Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019–2020 epidemic. Intensive Care Med.
XXXIX. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30(12):6808-6817.
XL. Gobierno de México. Boletín estadístico sobre exceso de mortalidad por todas las causas durante la emergencia por COVID-19 2020.